Overview

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
OSI Pharmaceuticals
Treatments:
Erlotinib Hydrochloride